Log in to save to my catalogue

In‐depth analysis of data from the RAS‐ALS study reveals new insights in rasagiline treatment for am...

In‐depth analysis of data from the RAS‐ALS study reveals new insights in rasagiline treatment for am...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2929059789

In‐depth analysis of data from the RAS‐ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis

About this item

Full title

In‐depth analysis of data from the RAS‐ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis

Publisher

England: John Wiley & Sons, Inc

Journal title

European journal of neurology, 2024-04, Vol.31 (4), p.e16204-n/a

Language

English

Formats

Publication information

Publisher

England: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Background and purpose
In 2016, we concluded a randomized controlled trial testing 1 mg rasagiline per day add‐on to standard therapy in 252 amyotrophic lateral sclerosis (ALS) patients. This article aims at better characterizing ALS patients who could possibly benefit from rasagiline by reporting new subgroup analysis and genetic data.
Metho...

Alternative Titles

Full title

In‐depth analysis of data from the RAS‐ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2929059789

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2929059789

Other Identifiers

ISSN

1351-5101,1468-1331

E-ISSN

1468-1331

DOI

10.1111/ene.16204

How to access this item